Organizing for drug-usage evaluation.

C Buchanan; P Sands

Home/Archive/PubMed

PubMed · 10128604

Organizing for drug-usage evaluation.

C Buchanan·P Sands

View original source ↗Export metadata ↓

Abstract

Because QA is the chief interest of the Joint Commission, hospital pharmacists must strive to have a well-organized DUE plan and process. However, merely satisfying a Joint Commission surveyor is not a good enough reason to invest in the DUE process. DUE is deceptively complex and labor intensive for hospital and medical staff alike. A better reason to plunge into DUE is to enable pharmacists to concurrently monitor pharmacotherapy, to intervene on behalf of patients, and to positively affect patients' therapeutic outcomes. Thereby, DUE really fits pharmacy's responsibility for pharmaceutical care.

Explore related subjects

Drug Utilization Evaluation Studies as Topic Forms and Records Control Georgia Hospital Bed Capacity, 500 and over Joint Commission on Accreditation of Healthcare Organizations Pharmacy Service, Hospital Quality Assurance, Health Care Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

C Buchanan, P Sands. 1991. Organizing for drug-usage evaluation.. https://pubmed.ncbi.nlm.nih.gov/10128604/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Determinants of diphemanil methylsulfate (Prantal) utilization: a survey of practice in the French neonatal and intensive care units].

UNLABELLED: Diphemanil methylsulfate (Prantal) is a quaternary ammonium with parasympathicolytic properties. It is used in premature and term neonates with bradycardias related to vagal hyper reflectivity (HRV). OBJECTIVES: To assess the use of Prantal in the French neonatal and intensive care units: its indications, its modalities of use, its side effects and the number of patients treated during 1 year (2004) in France. METHODS: A questionnaire was electronically sent to all neonatology units and all neonatal intensive care units in France. RESULTS: Among 202 units, 121 (60%) answered the questionnaire. Prantal was reported to be used in 51 (42.1%) units. Among them, 38 (31.4%) actually treated 169 patients in 2004 with a mean number of patients treated by unit of 4. The diagnostic of HRV was supported by: a history of malaise (84.3%), bradycardia (94.1%), oculocardiac reflex (74.5%), cardiac Holter (76.4%), cardiorespirographic recording (19.6%), esophageal pHmetry (35.2%) and esophageal fibroscopy (21.5%). The mean starting dosing was 4.7 mg/kg/d, the mean maximal dosing was 9 mg/kg/d and the mean daily intakes were initially 2.3 and secondary 2.9. Prantal dosing was adjusted to weight in 54.9%, every month in 85.7%. Treatment was stopped at the mean post-natal age of 6 months, mostly in a progressive manner and without monitoring help. CONCLUSION: Prantal was seldom used in 2004 in France for different reasons: HRV is an uncertain entity, the efficacy of Prantal has not been validated and atropinic side effects can be encountered.

Drug Utilization↗

PubMed2006

Drug utilization--a public health problem.

Explore the source record for details and available documents.

Drug Utilization↗

PubMed2006

Changing patterns of drug utilization in a neonatal intensive care population.

Newborns in the neonatal intensive care unit (NICU) typically are exposed to a large number of drugs and are especially vulnerable to adverse drug reactions. It is important to review changes in drug use patterns periodically in the NICU to identify newly introduced drugs as well as drugs with increasing use. The objective of this study was to determine the changes in drug utilization patterns over a 7-year period in an NICU population. Drug utilization of 2332 neonates treated at an intramural NICU between January 1, 1997 and December 31, 1998, and 2691 neonates between January 1, 2001 and June 30, 2004 was analyzed using chi-square tests, T tests, and linear regression. There was an increased utilization of antibiotics, central nervous system drugs, endocrine agents, cardiovascular and gastrointestinal drugs, and a decreased utilization of ophthalmic drugs. No changes in nutritional, biological, renal, and pulmonary drugs were observed. Some individual drug changes include an increased use of vancomycin, cefepime, caffeine, and a decreased use of morphine. Significant changes in drug utilization patterns in an NICU were observed during a 7-year period. These data are useful in monitoring drug resistance patterns, adverse drug reactions, and prioritizing areas of relevant therapeutic research and educational programs.

Drug Utilization↗